HPGC(SH:600664) Ge Long Hui A P P·2025-09-11 07:52Core Viewpoint - Harbin Pharmaceutical Group's subsidiary, Sanjing Mingshui, has received approval from the National Medical Products Administration for the supplementary application of Lercanidipine tablets, which have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - The approval of Lercanidipine tablets (4mg) enhances the market competitiveness of the product and is expected to increase its market share [1] - The drug is a highly selective calcium channel blocker that primarily dilates peripheral small arteries, reducing peripheral vascular resistance and lowering blood pressure [1] - The approval aligns with national policies that provide greater support for drugs that pass the consistency evaluation in areas such as medical insurance payments and procurement by medical institutions [1] Group 2: Strategic Implications for the Company - The successful evaluation of Lercanidipine tablets provides valuable experience for the company in conducting future consistency evaluations for other products [1]